Company Overview and News

HDIL to settle dues with J&K Bank by May 2

Mumbai : Housing Development and Infrastructure Ltd (HDIL) has offered to settle its outstanding dues with Jammu and Kashmir Bank by May 2 after the lender filed an insolvency plea against the company before the National Company Law Tribunal (NCLT).

Closing Bell: Sensex, Nifty close lower; banks drag but FMCG stocks support

2018-04-18 moneycontrol
3:30 pm Market Closing: Benchmark indices closed lower for the first time in last 10 consecutive sessions, dragged by banks. However, the upside in ITC capped losses.

Market Live: Sensex erases gains, Nifty below 10,550; banks under pressure

2018-04-18 moneycontrol
1:55 pm Earnings: Mastek's Q4 consolidated net profit increased to Rs 19.4 crore from Rs 18.4 crore and revenue grew by 6.8 percent to Rs 223.7 crore on sequential basis.

IDBI Bank Limited - Shareholders meeting

2018-04-18 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.

IDBI Bank to close loss-making branches, limit NPAs and focus on retail to get out of PCA: Deputy MD

2018-04-16 moneycontrol
IDBI Bank hopes to come out of the regulatory restrictive Prompt Corrective Action (PCA) after taking a host of measures, including closure/merger of branches, conversion of 31 loss-making branches into outlets, divestment in non-core assets, setting up of separate stressed assets management group and focus on retail and good quality corporate business.

Supreme Court asks Jaiprakash Associates to deposit Rs 100 crore by May 10

New Delhi: The Supreme Court today directed realty firm Jaiprakash Associates Limited (JAL) to deposit Rs 100 crore with its Registry by May 10. The bench headed by Chief Justice Dipak Misra also directed the Insolvency Resolution Professional (IRP) to consider the representation of JAL on revival plans as per law.

Lakshadweep ahead in race to buy Jaypee Infra

New Delhi : Dark horse Lakshadweep Pvt Ltd, a joint venture between Sudhir Valia-led Suraksha Asset Reconstruction Company and Mumbai-based Dosti Reality, has emerged as the front-runner to acquire Jaypee Infratech with a bid of around Rs 7,350 crore, but way lower than what the real estate developer had proposed to lenders a year back to pay off debt.

Lakshadeep emerges front-runner for Jaypee Infratech with Rs7,350 crore bid

2018-04-15 livemint
New Delhi: Dark horse Lakshadeep Pvt. Ltd has emerged as the front-runner to acquire Jaypee Infratech with a bid of around Rs7,350 crore, but way lower than what the real estate developer had proposed to lenders a year back to pay off debt.

RBI penalty not to have any material impact says IDBI Bank

Mumbai: State-run IDBI Bank on Thursday said a Rs 3 crore penalty imposed on it by the Reserve Bank of India (RBI) “will not have any material impact” on it. According to a BSE filing by IDBI Bank, the RBI imposed a Rs 3 crore penalty on it for non-compliance of ‘Income Recognition and Asset Classification’ (IRAC) norms.

RBI imposed Rs 3 crore fine on IDBI Bank violation of asset classification norms

Mumbai: The Reserve Bank of India (RBI) imposed monetary penalty worth Rs. 3 crore on IDBI Bank for not complying with the outlined norms related to reporting of bad loans. In an official notice, the RBI said the penalty was imposed on account of non-compliance with the directions issued on Income Recognition and Asset Classification (IRAC) norms.

IDBI Bank falls to 1-week low

2018-04-12 thehindubusinessline
IDBI Bank stock dropped as much as 3.1 per cent to Rs 69.8, lowest since April 4. - Bijoy Ghosh

Market Update: CNX IT zooms 3.7% as TCS, Infosys jumps over 2%; Nifty PSU bank falls 3%; Jubilant Food at new 52-week high

2018-04-12 moneycontrol
The Indian equity market was trading on a positive note on Thursday morning with the Nifty adding 20 points at 10,421 mark while the Sensex was up 51 points or 0.14 percent.

Market Update: Infosys jumps 4% ahead of results as Nifty IT zooms 5%; Tata Sponge up 14%; PSU banks drag

2018-04-12 moneycontrol
The Indian equity market was trading on a positive note on Thursday morning with the Nifty adding 37 points at 10,454 mark while the Sensex was up 174 points or 0.51 percent.

CBI probing another loan of Rs 5,280 crore taken by Mehul Choksi from ICICI-led banks

Mumbai: The CBI is probing yet another loan of Rs 5,280 crore extended by a consortium of 31 banks led by the ICICI Bank to companies of absconding billionaire jeweller Mehul Choksi, officials said on Wednesday.

RBI imposes Rs 3 cr penalty on IDBI Bank for violation of asset classification norms

2018-04-11 moneycontrol
The Reserve Bank of India has imposed a penalty of Rs 3 crore on IDBI bank for failing to comply with norms related to reporting of bad loans.

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...